Is The 21st Century Cures Act Good Or Bad For The Biopharmaceutical Industry?
The industry might benefit in the short-term by the more rapid approval of experimental medicines. However, the downstream consequences may outweigh any immediate benefits.
ليست هناك تعليقات:
إرسال تعليق